Glaucoma New Drug Approved By The FDA
Recently, Bausch + Lomb, a wholly owned subsidiary of Valeant Pharmaceuticals, announced that the FDA has approved the listing of the glaucoma new drug VYZULTA (latanoprostene bunod eye drops, 0.024%). VYZULTA is the first commercially available prostaglandin analogue to lower IOP.
Glaucoma and cataracts and macular degeneration are three major blinding eye diseases. The main cause is the intraocular aqueous humor can not be properly discharged, resulting in increased intraocular pressure. Long-term increase in intraocular pressure will oppress the optic nerve so that it is damaged, resulting in vision loss, or even blindness. Reducing IOP with existing medications or surgery can slow disease progression and reduce the risk of blindness.
This time, the approved VYZULTA is a once-a-day single drug therapy. The active ingredient in the drug, latanoprost acid and butanediol mononitrate, has a dual mechanism of action in the treatment of glaucoma-acting both on the uveal scleral pathways and on releasing Nitric oxide acts on the trabecular meshwork and Schlemm's canal to promote aqueous humor drainage. The efficacy of this two-pronged approach has been demonstrated in a series of clinical trials: VYZULTA demonstrated non-inferiority and superiority compared to timolol maleate eye drops; compared with latanoprost, VYZULTA can significantly reduce IOP. In addition, its short-term efficacy and long-term safety have also been confirmed.
Joseph C. Papa, Valeant's president and chief executive officer, said: "VYZULTA's approval of a new treatment for patients with glaucoma, which lastingly reduces IOP, is the only controlled risk of slowing the progression of the disease Factor and we look forward to bringing newer advances to patients with glaucoma by the end of this year. "
Original link: Bausch + Lomb And Nicox Announce FDA Approval Of VYZULTA ™ (Latanoprostene Bunod Ophthalmic Solution), 0.024%......